FDA Approves New Option in Obesity - Scorecard - MDSpire

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

  • By

  • Kathryn Wighton

  • February 23, 2026

  • 3 min

Share

Clinical Scorecard: FDA Approves New Option in Obesity

At a Glance

CategoryDetail
ConditionObesity
Key MechanismsSwallowable gastric balloon promotes satiety and reduces caloric intake.
Target PopulationAdults aged 22 to 65 years with obesity and at least one unsuccessful weight loss attempt.
Care SettingOutpatient office visit.

Key Highlights

  • FDA approved Allurion Gastric Balloon System for obesity management.
  • Device remains in stomach for approximately 4 months.
  • Average residence time of 15.3 weeks before natural passage.
  • Can be used in conjunction with lifestyle modification therapy.
  • Up to two balloons permitted during a 10-month period.

Guideline-Based Recommendations

Diagnosis

  • Assess body mass index (BMI) to confirm obesity diagnosis.

Management

  • Use the Allurion Gastric Balloon System alongside moderate-intensity lifestyle modification.

Monitoring & Follow-up

  • Monitor weight loss progress and adherence to lifestyle changes.

Risks

  • Potential for adverse effects similar to glucagon-like peptide-1 receptor agonists.

Patient & Prescribing Data

Estimated 80 million Americans with obesity within the indicated BMI range.

Device offers a non-surgical alternative to glucagon-like peptide-1s and bariatric surgery.

Clinical Best Practices

  • Incorporate lifestyle modification therapy with the gastric balloon treatment.
  • Consider patient history of weight loss attempts before prescribing.

Related Resources & Content

Original Source(s)

FDA Approves New Option in Obesity

  • by Kathryn Wighton

  • February 23, 2026

Related Content

Individualized osilodrostat treatment for patients with ACTH-dependent Cushing’s syndrome: real-world evidence

ACP Ranks Obesity Drug Options

A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.